Tenderwize
Retour à la recherche

Open-House-Biologika-Rabattverträge 2025-29 - Omalizumab

Techniker Krankenkasse·Hamburg, Germany·Deadline Oct 30, 2027 · 430 days left·Open·Supplies
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-29 - Omalizumab

5/100

Score d'opportunité

High riskLow complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

5 / 100

Complexité

30 / 100

Facteurs de risque

The XML change notice states the procedure was prematurely ended on 30.06.2026. The structured data still shows a futur...

No estimated contract value or framework maximum is provided. The financial attractiveness cannot be assessed.

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Weak opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Oct 2027
  • Conclusion of drug discount agreements for the active substance Omalizumab under German social law (§130a Abs. 8 SGB V).
  • Open House procedure: no individual negotiations, uniform conditions, no exclusivity.
Afficher le résumé complet

This notice concerns an Open-House procedure (not a classic EU procurement) for discount agreements on the active substance Omalizumab, under §130a Abs. 8 SGB V. The lead buyer is Techniker Krankenkasse. The procedure was originally open until October 2027, but a change notice (XML) indicates the procedure was prematurely ended on 30 June 2026. No estimated value is provided. Only one lot exists. Eligibility requires pharmaceutical entrepreneur status with proper authorization. Award criteria are not specified (placeholder only). Documents were not analyzed. Due to the premature termination, this tender is effectively closed.

Risques

The XML change notice states the procedure was prematurely ended on 30.06.2026. The structured data still shows a futur...

No estimated contract value or framework maximum is provided. The financial attractiveness cannot be assessed.

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur as defined in §4 Abs. 18 AMG with a valid authorization for the offered medicinal product.
  • Sitz in Germany, another EU member state, or EEA state (§9 Abs. 2 Satz 1 AMG).

Eligibility

  • Declaration of eligibility and reliability (Anlage 4) to be signed in text form.

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

No explicit award criteria; procedure is Open House with uniform conditions, not a competitive award.

Acheteur

Localisation

Hamburg, DEU

Identifiant

992-80116-93

Activité

Health

Lots (1)

LOT-0001

Open-House-Biologika-Rabattverträge 2025-29 - Omalizumab

Conclusion of discount agreements for Omalizumab with all eligible pharmaceutical entrepreneurs. No exclusivity, fixed conditions. Max contract duration 24 months from 01.11.2025 to 31.10.2027.

SuppliesEU fundedElectronic submission

Localisation

DE600, Germany

Durée

Oct 2025 - Oct 2027

Catégorie

Pharmaceutical products

Critères d'attribution

No explicit award criteria; procedure is Open House with uniform conditions, not a competitive award.

Date limite

Deadline Oct 30, 2027

Détails de la procédure

Date de publication
20 May 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
347743-2026

Documents (1)

Document de consultation 1

Appels d'offres similaires

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3